Literature DB >> 24861310

Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease.

Markus Mandler1, Lauren Walker, Radmila Santic, Peter Hanson, Ajeet Rijal Upadhaya, Sean J Colloby, Christopher M Morris, Dietmar R Thal, Alan J Thomas, Achim Schneeberger, Johannes Attems.   

Abstract

Pyroglutamylated amyloid-β (pE(3)-Aβ) has been suggested to play a major role in Alzheimer's disease (AD) pathogenesis as amyloid-β (Aβ) oligomers containing pE(3)-Aβ might initiate tau-dependent cytotoxicity. We aimed to further elucidate the associations among pE(3)-Aβ, full-length Aβ and hyperphosphorylated tau (HP-τ) in human brain tissue. We examined 41 post mortem brains of both AD (n = 18) and controls. Sections from frontal and entorhinal cortices were stained with pE(3)-Aβ, HP-τ and full-length Aβ antibodies. The respective loads were assessed using image analysis and western blot analysis was performed in a subset of cases. All loads were significantly higher in AD, but when using Aβ loads as independent variables only frontal pE(3)-Aβ load predicted AD. In frontal and entorhinal cortices pE(3)-Aβ load independently predicted HP-τ load while non-pE(3)-Aβ failed to do so. All loads correlated with the severity of AD neuropathology. However, partial correlation analysis revealed respective correlations in the frontal cortex only for pE(3)-Aβ load only while in the entorhinal cortex respective correlations were seen for both HP-τ and non-pE(3)-Aβ loads. Mini Mental State Examination scores were independently predicted by entorhinal HP-τ load and by frontal pE(3)-Aβ load. Here, we report an association between pE(3)-Aβ and HP-τ in human brain tissue and an influence of frontal pE(3)-Aβ on both the severity of AD neuropathology and clinical dementia. Our findings further support the notion that pE(3)-Aβ may represent an important link between Aβ and HP-τ, and investigations into its role as diagnostic and therapeutic target in AD are warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861310     DOI: 10.1007/s00401-014-1296-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  22 in total

Review 1.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

2.  Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Authors:  Adam P Gunn; Bruce X Wong; Timothy Johanssen; James C Griffith; Colin L Masters; Ashley I Bush; Kevin J Barnham; James A Duce; Robert A Cherny
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

3.  Post-Translational Modifications During Brain Development.

Authors:  Bradley J Smith; Victor Corasolla Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

4.  Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides.

Authors:  Greg Goldblatt; Jason O Matos; Jeremy Gornto; Suren A Tatulian
Journal:  Phys Chem Chem Phys       Date:  2015-12-28       Impact factor: 3.676

5.  An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Authors:  Jeffrey L Frost; Bin Liu; Jens-Ulrich Rahfeld; Martin Kleinschmidt; Brian O'Nuallain; Kevin X Le; Inge Lues; Barbara J Caldarone; Stephan Schilling; Hans-Ulrich Demuth; Cynthia A Lemere
Journal:  Neurobiol Aging       Date:  2015-08-31       Impact factor: 4.673

6.  Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer's disease.

Authors:  Mitsuru Shinohara; Shunsuke Koga; Takuya Konno; Jeremy Nix; Motoko Shinohara; Naoya Aoki; Pritam Das; Joseph E Parisi; Ronald C Petersen; Terrone L Rosenberry; Dennis W Dickson; Guojun Bu
Journal:  Brain       Date:  2017-12-01       Impact factor: 15.255

7.  Quantitative neuropathological assessment to investigate cerebral multi-morbidity.

Authors:  Johannes Attems; Janna H Neltner; Peter T Nelson
Journal:  Alzheimers Res Ther       Date:  2014-11-28       Impact factor: 6.982

8.  Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations.

Authors:  Ahmad A Khundakar; Peter S Hanson; Daniel Erskine; Nichola Z Lax; Joseph Roscamp; Evangelia Karyka; Eliona Tsefou; Preeti Singh; Simon J Cockell; Andrew Gribben; Lynne Ramsay; Peter G Blain; Urs P Mosimann; Deborah J Lett; Matthias Elstner; Douglass M Turnbull; Charles C Xiang; Michael J Brownstein; John T O'Brien; John-Paul Taylor; Johannes Attems; Alan J Thomas; Ian G McKeith; Christopher M Morris
Journal:  Acta Neuropathol Commun       Date:  2016-06-30       Impact factor: 7.801

Review 9.  Comparative neuropathology in aging primates: A perspective.

Authors:  Carmen Freire-Cobo; Melissa K Edler; Merina Varghese; Emily Munger; Jessie Laffey; Sophia Raia; Selena S In; Bridget Wicinski; Maria Medalla; Sylvia E Perez; Elliott J Mufson; Joseph M Erwin; Elaine E Guevara; Chet C Sherwood; Jennifer I Luebke; Agnès Lacreuse; Mary A Raghanti; Patrick R Hof
Journal:  Am J Primatol       Date:  2021-07-13       Impact factor: 2.371

10.  A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype.

Authors:  Michael Veitinger; Rudolf Oehler; Ellen Umlauf; Roland Baumgartner; Georg Schmidt; Christopher Gerner; Rita Babeluk; Johannes Attems; Goran Mitulovic; Eduard Rappold; John Lamont; Maria Zellner
Journal:  Acta Neuropathol       Date:  2014-09-24       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.